Literature DB >> 31666347

Response to Comment by Jonathan Weiss et al.

Eugen Tausch1, Stephan Stilgenbauer2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31666347      PMCID： PMC6821624          DOI： 10.3324/haematol.2019.236570

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Authors:  Piers Blombery; Mary Ann Anderson; Jia-Nan Gong; Rachel Thijssen; Richard W Birkinshaw; Ella R Thompson; Charis E Teh; Tamia Nguyen; Zhen Xu; Christoffer Flensburg; Thomas E Lew; Ian J Majewski; Daniel H D Gray; David A Westerman; Constantine S Tam; John F Seymour; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal:  Cancer Discov       Date:  2018-12-04       Impact factor: 39.397

2.  Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.

Authors:  Inhye E Ahn; Chingiz Underbayev; Adam Albitar; Sarah E M Herman; Xin Tian; Irina Maric; Diane C Arthur; Laura Wake; Stefania Pittaluga; Constance M Yuan; Maryalice Stetler-Stevenson; Susan Soto; Janet Valdez; Pia Nierman; Jennifer Lotter; Liqiang Xi; Mark Raffeld; Mohammed Farooqui; Maher Albitar; Adrian Wiestner
Journal:  Blood       Date:  2017-01-03       Impact factor: 22.113

3.  Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia.

Authors:  Eugen Tausch; William Close; Anna Dolnik; Johannes Bloehdorn; Brenda Chyla; Lars Bullinger; Hartmut Döhner; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

4.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Authors:  Jennifer A Woyach; Richard R Furman; Ta-Ming Liu; Hatice Gulcin Ozer; Marc Zapatka; Amy S Ruppert; Ling Xue; Daniel Hsieh-Hsin Li; Susanne M Steggerda; Matthias Versele; Sandeep S Dave; Jenny Zhang; Ayse Selen Yilmaz; Samantha M Jaglowski; Kristie A Blum; Arletta Lozanski; Gerard Lozanski; Danelle F James; Jacqueline C Barrientos; Peter Lichter; Stephan Stilgenbauer; Joseph J Buggy; Betty Y Chang; Amy J Johnson; John C Byrd
Journal:  N Engl J Med       Date:  2014-05-28       Impact factor: 91.245

5.  Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Authors:  Carmen D Herling; Nima Abedpour; Jonathan Weiss; Anna Schmitt; Ron Daniel Jachimowicz; Olaf Merkel; Maria Cartolano; Sebastian Oberbeck; Petra Mayer; Valeska Berg; Daniel Thomalla; Nadine Kutsch; Marius Stiefelhagen; Paula Cramer; Clemens-Martin Wendtner; Thorsten Persigehl; Andreas Saleh; Janine Altmüller; Peter Nürnberg; Christian Pallasch; Viktor Achter; Ulrich Lang; Barbara Eichhorst; Roberta Castiglione; Stephan C Schäfer; Reinhard Büttner; Karl-Anton Kreuzer; Hans Christian Reinhardt; Michael Hallek; Lukas P Frenzel; Martin Peifer
Journal:  Nat Commun       Date:  2018-02-20       Impact factor: 14.919
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.